周二盘中，制药巨头辉瑞（PFE）股价出现大幅下跌，跌幅达5.04%。这一显著跌幅主要归因于华尔街知名投行高盛对辉瑞股票评级的下调。
据报道，高盛分析师将辉瑞的股票评级从"买入"下调至"中性"，同时大幅下调了目标价，从此前的32.00美元降至25.00美元。这一评级调整反映了分析师对辉瑞未来业绩增长的担忧，可能与公司在后疫情时代面临的挑战有关。
值得注意的是，辉瑞作为全球最大的制药公司之一，年销售额接近500亿美元（不包括与新冠相关的产品销售额）。公司主要业务集中在处方药和疫苗领域，畅销产品包括肺炎球菌疫苗Prevnar 13、抗癌药物Ibrance和心血管治疗药物Eliquis。然而，高盛此次评级下调可能暗示投资者需要重新评估辉瑞的长期增长前景。这一消息引发了市场的强烈反应，导致辉瑞股价在交易时段内大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.